Haemonetics 4th Quarter and Fiscal 2019 Earnings Release Available on Investor Relations Website
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Haemonetics (HAE) Tops Q4 EPS by 6c, Offers Guidance, Approves $500M Buyback
May 7, 2019 6:16 AM EDTHaemonetics (NYSE: HAE) reported Q4 EPS of $0.61, $0.06 better than the analyst estimate of $0.55. Revenue for the quarter came in at $249.3 million versus the consensus estimate of $250.63 million.
GUIDANCE:
Haemonetics sees FY2020 EPS of $2.80-$3.00, versus the consensus of $2.89.
SHARE REPURCHASE PROGRAM The Company announced that its Board of Directors recently authorized the repurchase of... More
